Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $64,410 - $71,518
-1,011 Reduced 13.4%
6,531 $418,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $32,395 - $36,743
-493 Reduced 6.14%
7,542 $523,000
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $453,611 - $537,140
-6,624 Reduced 45.19%
8,035 $578,000
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $0 - $153
2 Added 0.01%
14,659 $1.04 Million
Q2 2022

Jul 28, 2022

SELL
$72.62 - $79.98 $136,017 - $149,802
-1,873 Reduced 11.33%
14,657 $1.13 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $123,697 - $148,324
2,012 Added 13.86%
16,530 $1.21 Million
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $159,710 - $186,184
-2,978 Reduced 17.02%
14,518 $905,000
Q3 2021

Oct 06, 2021

BUY
$59.17 - $69.31 $25,265 - $29,595
427 Added 2.5%
17,496 $1.04 Million
Q2 2021

Jul 06, 2021

BUY
$61.91 - $67.42 $571,800 - $622,691
9,236 Added 117.91%
17,069 $1.14 Million
Q1 2021

May 26, 2021

BUY
$59.34 - $66.74 $241,929 - $272,098
4,077 Added 108.55%
7,833 $494,000
Q4 2020

Feb 01, 2021

BUY
$57.74 - $65.43 $216,871 - $245,755
3,756 New
3,756 $233,000
Q3 2020

Oct 15, 2020

SELL
$57.43 - $63.64 $224,034 - $248,259
-3,901 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$46.4 - $67.43 $4,593 - $6,675
-99 Reduced 2.48%
3,901 $217,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $196,840 - $256,760
4,000 New
4,000 $257,000
Q2 2018

Jul 31, 2018

SELL
$50.53 - $62.98 $192,721 - $240,205
-3,814 Closed
0 $0
Q3 2017

Nov 07, 2017

SELL
$55.23 - $63.74 $13,807 - $15,935
-250 Reduced 6.15%
3,814 $243,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,064
4,064 $226,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track First Dallas Securities Inc. Portfolio

Follow First Dallas Securities Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Dallas Securities Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Dallas Securities Inc. with notifications on news.